An example is the unprecedented success of the combined use of hypomethylating agents e.g., 5-azacytidine and decitabine in combination with the Bcl-2 inhibitor venetoclax for treating acute myeloid leukemia (AML). The gene discussed is BCL2; the disease is acute myeloid leukemia.